Review of the apoptosis pathways in pancreatic cancer and the anti-apoptotic effects of the novel sea cucumber compound, frondoside A

Annals of the New York Academy of Sciences

Volumn 1138, Issue , 2008, Pages 181-198

  Li, X ^a,e   Roginsky, A B ^a   Ding, X Z ^a   Woodward, C ^b   Collin, P ^b   Newman, R A ^c   Bell Jr , R H ^a   Adrian, T E ^a,d  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Coastside Research ^*  (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

^e Wujing General Hospital   (China)

Author keywords

Apoptosis pathways; Frondoside A; Pancreatic cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 7; CASPASE 9; FRONDOSIDE A; LIPOCORTIN 5; NATURAL PRODUCT; PROPIDIUM IODIDE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN MCL 1; PROTEIN P21; THYMIDINE; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER INHIBITION; CELL COUNT; CELL DEATH; CELL GROWTH; CELL POPULATION; CELL PROLIFERATION; CELL STRUCTURE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG CHOICE; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MITOCHONDRION; MOUSE; NICK END LABELING; NONHUMAN; PANCREAS CANCER; PANCREAS CELL; PROTEIN BINDING; PROTEIN EXPRESSION; SEA CUCUMBER; STAINING; TUMOR XENOGRAFT; UPREGULATION; WESTERN BLOTTING;

CUCUMARIA FRONDOSA; HOLOTHUROIDEA; MUS;

EID: 53149130259     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1414.025     Document Type: Conference Paper

References (87)

1. Jema, A., R. Siegel, E. Ward, et al. 2006. Cancer statistics, 2006. CA. Cancer J. Clin. 56 : 106 130.
2. Cardenes, H.R., E.G. Chiorean, J.J. DeWitt, et al. 2006. Locally advanced pancreatic cancer: current therapeutic approach. Ocologist 11 : 612 623.
3. Cameron, J.L., H.A. Pitt & C.J. Yeo. 1993. One hundred and forty-five consecutive pancreatico-duodenectomies without mortality. Ann. Surg. 217 : 430 438.
4. Carpelan-Holmström, M., S. Nordling, E. Pukkala, et al. 2005. Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry. Pancreas 54 : 385 387.
5. Serafini, F.M. & A.S. Rosemurgy. 2000. New direction in systemic therapy of pancreatic cancer. Cancer Control 7 : 437 444.
6. Giovannetti, E., V. Mey, S. Nannizzi, et al. 2006. Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer. Mol. Cancer Ther. 6 : 1387 1395.
7. Nakano, Y., S. Tanno, K. Koizumi, et al. 2007. Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells. Br. J. Cancer 96 : 457 463.
8. Talar-Wojnarowska, R. & E. Malecka-Panas. 2006. Molecular pathogenesis of pancreatic adenocarcinoma: potential clinical implications. Med. Sci. Monit. 2 : 186 193.
9. Schneider, G. & R.M. Schmid. 2003. Genetic alterations in pancreatic carcinoma. Mol. Cancer 2 : 15.
10. Okada, H. & T.W. Mak. 2004. Pathways of apoptotic and non-apoptotic death in tumor cells. Nature Rev. Cancer 4 : 592 603.
11. Ghobrial, I.M., T.E. Witzig & A.A. Adjei. 2005. Targeting apoptosis pathways in cancer therapy. CA Cancer J. Clin. 55 : 178 194.
12. Elnemr, A., T. Ohta, A. Yachie, et al. 2001. Human pancreatic cancer cells disable function of Fas receptors at several levels in Fas signal transduction pathway. Int. J. Oncol. 2 : 311 316.
13. Matsuzaki, H., B.M. Schmied, A. Ulrich, et al. 2001. Combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and actinomycin D induces apoptosis even in TRAIL-resistant human pancreatic cancer cells. Clin. Cancer Res. 2 : 407 414.
14. Vogler, M., K. Durr, M. Jovanovic, et al. 2007. Regulation of TRAIL-induced apoptosis by XIAP in pancreatic cancer cells. Oncogene 26 : 248 257.
15. L protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor- mediated apoptosis. Oncogene 19 : 5477 5486.
16. Li, X., X. Ding & T.E. Adrian. 2003. Arsenic trioxide induces apoptosis in pancreatic cancer cells via changes in cell cycle, caspase activation, and GADD expression. Pancreas 27 : 174 179.
17. Tong, W.G., X.Z. Ding, R.C. Witt & T.E. Adrian. 2002. Lipoxygenase inhibitors attenuate growth of human pancreatic cancer xenografts and induce apoptosis through the mitochondrial pathway. Mol. Cancer Ther. 1 : 929 935.
18. L interacts with Apaf-1 and inhibits Apaf-1-dependent caspase-9 activation. Proc. Natl. Acad. Sci. U.S.A. 95 : 4386 4391.
19. L antisense oligonucleotides induce apoptosis and increase sensitivity of pancreatic cancer cells to gemcitabine. Int. J. Cancer 94 : 268 274.
20. Shi, X., S. Liu, J. Kleeff, et al. 2002. Acquired resistance of pancreatic cancer cells towards 5-fluorouracil and gemcitabine is associated with altered expression of apoptosis-regulating genes. Oncology 62 : 354 362.
21. Xu, Z.W., H. Friess, M.W. Büchler & M. Solioz. 2002. Overexpression of Bax sensitizes human pancreatic cancer cells to apoptosis induced by chemotherapeutic agents. Cancer Chemother. Pharmacol. 49 : 504 510.
22. Baell, J.B. & D.C. Huang. 2002. Prospects for targeting the Bcl-2 family of proteins to develop novel cytotoxic drugs. Biochem. Pharmacol. 64 : 851 863.
23. Krueger, A., S. Baumann, P.H. Krammer & S. Kirchoff. 2001. FLICE-inhibitory proteins: Regulators of death receptor-mediated apoptosis. Mol. Cell Biol. 21 : 8247 8254.
24. Kim, Y., N. Suh, M. Sporn & J.C. Reed. 2002. An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis. J. Biol. Chem. 277 : 22320 22329.
25. Kataoka, T., R.C. Budd, N. Holler, et al. 2000. The caspase-8 inhibitor FLIP promotes activation of NFκB and Erk signaling pathways. Curr. Biol. 10 : 640 648.
26. Bharti, A.C. & B.B. Aggarwal. 2002. Nuclear factor-κ-B and cancer: Its role in prevention and therapy. Biochem. Pharmacol. 64 : 883 888.
27. Deveraux, Q.L. & J.C. Reed. 1999. IAP family proteins-suppressors of apoptosis. Genes Dev. 13 : 239 252.
28. Tamm, I., Y. Wang, E. Sausville, et al. 1998. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res. 58 : 5315 5320.
29. Bhanot, U., R. Heydrich, P. Moller & C. Hasel. 2006. Survivin expression in pancreatic intraepithelial neoplasia (PanIN): steady increase along the developmental stages of pancreatic ductal adenocarcinoma. Am. J. Surg. Pathol. 30 : 754 759.
30. Shrikhande, S.V., J. Kleeff, H. Kayed, et al. 2006. Silencing of X-linked inhibitor of apoptosis (XIAP) decreases gemcitabine resistance in pancreatic cancer cells. Anticancer Res. 26 : 3265 3273.
31. Li, Y., Z. Jian, K. Xia, et al. 2006. XIAP is related to the chemoresistance and inhibited its expression by RNA interference sensitize pancreatic carcinoma cells to chemotherapeutics. Pancreas 32 : 288 296.
32. Guan, H.T., X.H. Xue, Z.J. Dai, et al. 2006. Down-regulation of survivin expression by small interfering RNA induces pancreatic cancer cell apoptosis and enhances its radiosensitivity. World J. Gastroenterol. 12 : 2901 2907.
33. Verhagan, A.M., P.G. Ekert, M. Pakusch, et al. 2000. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 102 : 43 53.
34. Arnt, C.R., M.V. Chiorean, M.P. Heldebrant, et al. 2002. Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP in situ. J. Biol. Chem. 277 : 44236 44243.
35. Satoh, K., K. Kaneko, M. Hirota, et al. 2000. The pattern of CPP32/caspase-3 expression reflects the biological behavior of the human pancreatic duct cell tumors. Pancreas 21 : 532 537.
36. Roy, S., C.I. Bayly, Y. Gareau, et al. 2001. Maintenance of caspase-3 proenzyme dormancy by an intrinsic "safety catch" regulatory tripeptide. Proc. Natl. Acad. Sci. U.S.A. 98 : 6132 6137.
37. Putt, K.S., G.W. Chen, J.M. Pearson, et al. 2006. Small-molecule activation of procaspase-3 to caspase-3 as a personalized anticancer strategy. Nature Chem. Biol. 2 : 543 550.
38. KIP1 expression. J. Biol. Chem. 275 : 24500 24505.
39. L levels in vivo. J. Exp. Med. 191 : 1721 1734.
40. Gilmore, A.P., A.J. Valentjin, P. Wang, et al. 2002. Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulin-like growth factor receptor. J. Biol. Chem. 277 : 27643 27650.
41. Kermer, P., R. Ankerhold, N. Klocker, et al. 2000. Caspase-9: Involvement in secondary death of axotomized rat retinal ganglion cells in vivo. Brain Res. Mol. Brain Res. 85 : 144 150.
42. Ng, S.S.W., M.S. Tsao, S. Chow & D.W. Hedley. 2000. Inhibition of phophatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. Cancer Res. 60 : 5451 5455.
43. Ng, S.S., M.S. Tsau, T. Nicklee & D.W. Hedley. 2001. Wortmannin inhibits pkb/akt phosphorylation and promotes gemcitabine antitumor activity in orthotopic human pancreatic cancer xenografts in immunodeficient mice. Clin. Cancer Res. 7 : 3269 3275.
44. Korc, M., B. Chandraseker, Y. Yamanaka, et al. 1992. Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with comcomitant increases in the level of epidermal growth factor and transforming growth factor alpha. J. Clin. Invest. 90 : 1352 1360.
45. Salabat, M.R., X.Z. Ding, J.B. Flesche, et al. 2006. On the mechanisms of 12-otetradecanoylphorbol-13-acetate -induced growth arrest in pancreatic cancer cells. Pancreas 33 : 148 155.
46. Bivona, T.G., S.E. Quatela, B.O. Bodemann, et al. 2006. PKC regulates a farnesyl-electrostatic switch on K-Ras that promotes its association with Bcl-XL on mitochondria and induces apoptosis. Mol. Cell 21 : 481 493.
47. Moore, M.J., D. Goldstein, J. Hamm, et al. 2005. Erlotinib improves survival when added to gemcitabine in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). J. Clin. Oncology 23 (Suppl. 1.
48. Tang, P.A., M.S. Tsao & M.J. Moore. 2006. A review of erlotinib and its clinical use. Expert. Opin. Pharmacother. 7 : 177 193.
49. Kwak, E.L., J. Jankowski, S.P. Thayer, et al. 2006. Epidermal growth factor receptor kinase domaine mutations in esophageal and pancreatic adenocarcinomas. Clin. Cancer Res. 12 : 4283 4287.
50. Xiong, H.Q., A. Rosenberg, A. LoBuglio, et al. 2004. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II trial. J. Clin. Oncol. 22 : 2610 2616.
51. Graeven, U., B. Kremer, T. Sudhoff, et al. 2006. Phase I study of the humanized anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer. Br. J. Cancer 94 : 1293 1299.
52. Messersmith, W.A., M. Hidalgo, M. Carducci & S.G. Eckhardt. 2006. Novel targets in solid tumors: MEK inhibitors. Clin. Adv. Hematol. Oncol. 4 : 831 836.
53. Safran, H., D. Iannitti, R. Ramanathan, et al. 2004. Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress Her-2/neu. Cancer Invest. 22 : 706 712.
54. Karin, M. & A. Lin. 2002. NF-κB at the crossroads of life and death. Nature Immunol. 3 : 221 222.
55. Arlt, A., J. Vorndamm, M. Breitenbroich, et al. 2001. Inhibition of NF-κB sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin. Oncogene 20 : 859 868.
56. Li, Y., F. Ahmed, S. Ali, et al. 2005. Inactivation of nuclear factor κB by soy isoflavone genestein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. Cancer Res. 65 : 6934 6942.
57. Ghaneh, P., W. Greenhalf, M. Humphreys, et al. 2001. Adenovirus-mediated transfer of p53 and p16 (INK4a) results in pancreatic cancer regression in vitro and in vivo. Gene Ther. 8 : 199 208.
58. Ding, X.Z., C.A. Kuszynski, T.H. El-Metwally & T.E. Adrian. 1999. Lipoxygenase inhibitors induce apoptosis, morphological changes and carbonic anhydrase expression in pancreatic cancer cells. Biochem. Biophys. Res. Comm. 266 : 392 399.
59. Ding, X.Z., W.G. Tong & T.E. Adrian. 2000. Blockade of cyclooxygenase-2 inhibits proliferation and induces apoptosis in human pancreatic cancer cells. Anticancer Res. 20 : 2625 2631.
60. Hennig, R., X.Z. Ding, W.G. Tong, et al. 2002. 5-Lipoxygenase and leukotriene B(4) receptor are expressed in human pancreatic cancers but not in pancreatic ducts in normal tissue. Am. J. Pathol. 161 : 421 428.
61. Hennig, R., P. Grippo, X.Z. Ding, et al. 2005. 5-Lipoxygenase, a marker for early pancreatic intraepithelial neoplastic lesions. Cancer Res. 65 : 6011 6016.
62. Ding, X.Z., W.G. Tong & T.E. Adrian. 2001. 12-lipoxygenase metabolite 12(S)-HETE stimulates human pancreatic cancer cell proliferation via protein tyrosine phosphorylation and ERK activation. Int. J. Cancer 94 : 630 636.
63. Ding, X.Z., W.G. Tong & T.E. Adrian. 2003. Multiple signal pathways are involved in the mitogenic effect of 5(S)-HETE in human pancreatic cancer. Oncology 65 : 285 294.
64. Tong, W.G., X.Z. Ding & T.E. Adrian. 2002. Leukotriene B4 receptor antagonist LY293111 inhibits proliferation and induces apoptosis in human pancreatic cancer cells. Clin. Cancer Res. 8 : 3232 3242.
65. Hennig, R., J. Ventura, R. Segersvard, et al. 2005. LY293111 improves efficacy of gemcitabine therapy on pancreatic cancer in a fluorescent orthotopic model in athymic mice. Neoplasia 7 : 417 425.
66. Ding, X.Z. & T.E. Adrian. 2002. Resveratrol inhibits proliferation and induces apoptosis in human pancreatic cancer cells. Pancreas 25 : e71 e76.
67. Ujiki, M.B., X.Z. Ding, M.R. Salabat, et al. 2006. Apigenin inhibits pancreatic cancer cell proliferation through G2/M cell cycle arrest. Mol. Cancer 5 : 76.
68. Park, Y.J., J. Wen, S. Bang, et al. 2005. [6]-Gingerol induces cell cycle arrest and cell death of mutant p53-expressing pancreatic cancer cells. Yonsei Med. J. 47 : 688 697.
69. Ujiki, M.B., B. Milam, X.Z. Ding, et al. 2006. A novel peptide sansalvamide analogue inhibits pancreatic cancer cell growth through G0/G1 cell-cycle arrest. Biochem. Biophys. Res. Commun. 340 : 1224 1228.
70. Elyakov, G.B., T.A. Kuznetsova, et al. 1969. A chemical investigation of the trepeng (Stychopus japonicus Selenka): the structure of triterpenoid aglycones obtained from trepeng glycosides. Tetrahedron Lett. 15 : 1151 1154.
71. Maltsev, I.I., V.A. Stonik, A.I. Kalinovsky & G.B. Elyakov. 1984. Triterpene glycosides from sea cucumber Stichopus japonicus Selenka. Comp. Biochem. Physiol. B. 78 : 421 426.
72. Halstead, B.W. 1969. Marine biotoxins: a new source of medicinals. Lloydia 32 : 484 488.
73. Kashiwada, Y., T. Fujioka, K. Mihashi, et al. 1997. Antitumor agents.180. Chemical studies and cytotoxic evaluation of cumingianosides and cumindysoside A, antileukemic triterpene glucosides with a 14, 18-cycloapotirucallane skeleton. J. Nat. Prod. 60 : 1105 1114.
74. Friess, S.L., F.G. Standaert, E.R. Whitcomb, et al. 1960. Some pharmacologic properties of holothurin A a glycosidic mixture from the sea cucumber. Ann. N. Y. Acad. Sci. 17 : 893 901.
75. Pettit, G.R., C.L. Herald & D.L. Herald. 1976. Antineoplastic agents XLV: sea cucumber cytotoxic saponins. J. Pharm. Sci. 65 : 1558 1559.
76. Friess, S.L., F.G. Standaert, E.R. Whitcomb, et al. 1959. Some pharmacologic properties of holothurin, an active neurotoxin from the sea cucumber. J. Pharm. Exp. Ther. 126 : 323 329.
77. Kuznetsova, T.A., M.M. Anisimov, A.M. Popov, et al. 1982. A comparative study in vitro of physiological activity of triterpene glycosides of marine invertebrates of echinoderm type. Comp. Biochem. Physiol. C. 73 : 41 43.
78. Zou, Z.R., Y.H. Yi, H.M. Wu, et al. 2003. Intercedensides A-C, three new cytotoxic triterpene glycosides from the sea cucumber Mensamaria intercedens Lampert. J. Nat. Prod. 66 : 1055 1060.
79. Naito, K., N. Kanbayashi, S. Nakajima, et al. 1994. Inhibition of growth of human tumor cells in nude mice by a metalloproteinase inhibitor. Int. J. Cancer 58 : 730 735.
80. Waldman, T., K.W. Kinzler & B. Vogelstein. 1995. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res. 55 : 5187 5190.
81. Houghton, J.A. 1999. Apoptosis and drug response. Curr. Opin. Oncol. 11 : 475 481.
82. Thornberry, N.A. & Y. Lazebnik. 1998. Caspase: enemies within. Science 281 : 1312 1316.
83. Mancini, M., D.W. Nicholson, S. Roy, et al. 1998. The caspase-3 precursor has a cytosolic and mitochondrial distribution: implications for apoptotic signaling. J. Cell Biol. 140 : 1485 1495.
84. Kothakota, S., T. Azuma, C. Reinhard, et al. 1997. Caspase-3 generated fragment of gelsolin: effector of morphological change in apoptosis. Science 278 : 294 298.
85. Chai, J., E. Shiozaki, S.M. Srinivasula, et al. 2001. Structure basis of caspase-7 inhibition by XIAP. Cell 104 : 769 780.
86. Boucher, M.J., J. Morisset, P.H. Vachon, et al. 2000. MEK/ERK signaling pathway regulates the expression of Bcl-2, Bcl-X(L), and Mcl-1 and promotes survival of human pancreatic cancer cells. J. Cell. Biochem. 79 : 355 369.
87. Harris, M.H. & C.B. Thompson. 2000. The role of the Bcl-2 family in the regulation of outer mitochondrial membrane permeability. Cell Death Differ. 7 : 1182 1191.